2. Forward Looking Statements
This presentation contains certain forward looking statements relating to the company’s
business prospects and the development and commercialization of REOLYSIN®, a therapeutic
reovirus. These statements are based on management’s current expectations and beliefs and
are subject to a number of factors which involve known and unknown risks, delays,
uncertainties and other factors not under the company’s control which may cause actual
results, performance or achievements of the company to be materially different from the
results, performance or other expectations implied by these forward looking statements.
In any forward looking statement in which Oncolytics Biotech® Inc. expresses an expectation or
belief as to future results, such expectations or beliefs are expressed in good faith and are
believed to have a reasonable basis, but there can be no assurance that the statement or
expectation or belief will be achieved. These factors include results of current or pending clinical
trials, risks associated with intellectual property protection, financial projections, actions by the
FDA/HPB/MHRA and those other factors detailed in the company’s filings with SEDAR and the
Securities and Exchange Commission. Oncolytics does not undertake an obligation to update
the forward looking statements, except as required by applicable laws.
2
3. Investment Highlights
3
Novel immuno-oncology (I/O) viral-agent for systemic administration
exploiting dual activity by cancer cell lysis and anti-tumor immunity
Additional randomized Ph 2 studies to generate OS data in 2017
Pending data in Breast, Ovarian, NSCLC & Colorectal
Near-term focus on chemo-combos for late-stage clinical development
Potential to establish REOLYSIN® as a backbone I/O agent in
combination with checkpoint inhibitors and IMiDs
Extensive patient safety data showing no added significant toxicity
when used as combination with chemotherapy
Manufacturing at scale with sufficient supplies on hand to support late/
stage development and early commercialization
4. The Landscape
4
AZ / Medimmune
Omnis Pharma Undisclosed
Combine IO portfolio with oncolytic virus
programme
Valeant
Dendreon $495M
Metastatic prostate cancer
Amgen
BioVEx Upfront $425M
Milestones $575M
Ph 3 oncolytic vaccine for H&N and
melanoma
Bristol-Myers Squibb
PsiOxus Upfront $50M
Milestones $886M
NG-348, a pre-clinical oncolytic virus for
solid tumors – plus royalties on net sales
Boehringer Ingelheim
ViraTherapeutics up to €210M
Pre-clinical oncolytic virus
Amgen
Onyx $10.4B
Kyprolis – approved for multiple myeloma
Pfizer
Medivation $14B
XTANDI – approved for advanced
metastatic prostate cancer
Pfizer
Western Oncolytics Undisclosed
Novel oncolytic vaccinia virus
Ipsen
Merrimack Upfront $575M
Milestones $450M
ONIVYDE – approved for pancreatic cancer
DOXIL – approved for ovarian cancer
5. Oncolytics Overview
Defined clinical program and
potential registration pathway
Final formulation
produced
• 100L scale under
cGMP
900+ patients
treated systemically
• Strong safety profile
New class of
immuno-oncology
viral agent
5
6. What is REOLYSIN®
First in class systemically
administered immuno-
oncology viral agent for
solid tumors and
heme malignancies
Proprietary isolate of the
unmodified reovirus
Non-pathogenic
6
7. The Future of REOLYSIN® as an
Immuno-Oncology Viral Agent
REOLYSIN®
ClinicalDevelopmentPlan
Chemo Combinations
Immunotherapy
Combinations
Targeted / IMiD
Combinations
Continuing positive benefit-risk profile
7
Conceptual data
8. What’s New and Lessons Learned
• Strong OS data trumps Progression Free Survival (PFS)
• Emerging OS results support mechanism of action (MOA)
o Pancreatic, Lung & Colorectal
1 Hodi, NEJM 2010, 363:711; 2 Borghaei, NEJM 2015,371:1627; 3 Ferris, NEJM 2016, 375:1856
Emerging paradigm from immune checkpoint inhibition studies
1. Chemo impacts the overall response rate (ORR) and PFS because of its rapid
antitumor response, yet OS is not always improved
2. Immunotherapies (e.g., immune checkpoint inhibitors (ICI)), by contrast, may not
improve ORR or PFS but survival rates are consistently better than with
chemotherapy in certain cancers 1-3
Melanoma
treated with ICI
vs. chemo
Ipilimumab
SOC
Hodi et.al., NEJM 2010
Ipilimumab
SOC
Overall SurvivalProgression Free Survival
8
13. Clinical Development Plan: Pathways
The clinical development plan addresses drug combinations that
can potentially boost each response of the MOA
1. Chemo combinations (direct cell lysis):
The basis of the first registration pathway
2. Immunotherapy combinations (adaptive immune response):
Approaches with checkpoint inhibitors embodied in the ongoing
REOLYSIN® + pembrolizumab study and possible future collaborations
3. Combination with IMiDs / targeted therapy (innate immune response):
The proposed approach to be used in collaboration with Myeloma UK where
we expect enhancement of innate immunity
13
14. Path 1: Chemotherapy Combinations
Metastatic Pancreatic Cancer (1st Line)
o Regulatory Status
o Orphan Drug Designation Granted (FDA / EMA)
o Seeking scientific advice - potential for
Fast-Track Designation
o Preparing for End of Phase 2 Meeting
14
15. Path 1: Chemotherapy Combinations
15
Metastatic Pancreatic Cancer (1st Line)
o Excellent safety and encouraging benefit in 2-year survival in single arm Ph 2 studies:
Randomized Intent To Treat (NCI-8601)
o Carbotax + REO (n=36)
o Carbotax (n=37)
Randomized Excluding Crossover
o Carbotax + REO (n=36)
o Carbotax (n=20)
Single Arm (REO 017)
o REO + Gemcitabine
(n=34)
Reo + gem
2y-OS = 24 %
16. Path 1: Chemotherapy Combinations
Metastatic Pancreatic Cancer (1st Line)
o REO 017 vs historical controls:
16
Median OS
(months)
1-year survival 1.5-year survival 2-year survival
Burris et al., 1997
Gemcitabine (n=63) 5.65 18% NR NR
5-Fluorauracil (n=63) 4.41 2% NR NR
Conroy et al., 2011
Gemcitabine (n=171) 6.8 (5.5-7.6) NR 6% NR
Folfirinox (n=171) 11.1 (9.0-13.1) NR 19% NR
Von Hoff et al., 2013
Gemcitabine (n=430) 6.7 (6.0-7.2) 22% NR 4% (2%-7%)
Gem + nab paclitaxel (n=431) 8.5 (7.9-9.5) 35% NR 9% (6%-13%)
REO 017
REOLYSIN® + Gemcitabine (n=34) 10.2 46% NR 24%
17. Path 1: Chemotherapy Combinations
Pending survival data expected to read out in 2017
Study Phase Tumor Type Enrollment Timeline
NCI-GOG 0186H
(REO + paclitaxel) 2
Ovarian Epithelial, Fallopian Tube,
Primary Peritoneal Cancer
n=100 1H 2017
NCIC-CTG IND.213
(REO + paclitaxel) 2
Advanced or Metastatic Breast
Cancer
n=74 1H 2017
NCIC-CTG IND.209
(REO + docetaxel) 2
Recurrent or Metastatic Castration
Resistant Prostate Cancer
n=85 2H 2017
NCIC-CTG IND.210
(REO + FOLFOX6 + Avastin) 2 Recurrent Colorectal Cancer n=109 2H 2017
NCIC-CTG IND.211
(REO + docetaxel or
pemetrexed)
2
Previously Treated Advanced or
Metastatic NSCLC
n=90 2H 2017
17
18. Path 2: Immunotherapy Combinations
REO + Pembrolizumab (anti-PD-1 antibody)
in pancreatic cancer (REO 024)
o Establish safety profile
o Final analysis in 2017
Future potential collaborations pending
Rajani, Viruses 2015, 7:588; Noonan, Mol Ther 2016;
Rajani, Mol Ther 2016,24:166
18
19. Path 3: Targeted/IMiD Combinations
REO + Pomalidomide in multiple myeloma
o Establish safety profile
o Ongoing collaboration with Myeloma UK
Enhancement of Innate
Immune Response:
REOLYSIN® + IMiDs
REOLYSIN® alone
REOLYSIN® + IMiDs
Release of
inflammatory
cytokines
Increased
activation of
NK cells
Release of
inflammatory
cytokines
Activation
of NK
cells
+ IMiDs
19
21. REOLYSIN® and Safety
1,100+ patients treated, 900+ intravenously
No maximum tolerated dose (MTD) reached to date
Monotherapy Toxicity Symptoms
Symptoms frequently observed from day 2 of treatment
and usually lasted < 6 hours
Intravenous local
Toxicities have generally been mild (grade 1 or 2) and included chills, fever,
headache, cough, myalgia, runny nose, sore throat, fatigue, and grade 1 or 2
lymphopenia or neutropenia
Transient grade 3 and 4 toxicities included lymphopenia or neutropenia
21
23. Patent Portfolio
More than 440 patents issued
worldwide, including 61 US and
20 Canadian
Reovirus issue patent claims cover:
• Compositions of matter comprising reovirus
• Pharmaceutical use of reoviruses to treat
neoplasia and cellular proliferative diseases
• Combination therapy with radiation,
chemotherapy and/or immune suppressants
• Methods for manufacturing reovirus and
screening for susceptibility to reovirus
• Pharmaceutical use of reoviruses in
transplantation procedures
Over 60 pending
applications worldwide
23
25. Experienced Leadership
25
Matt Coffey, PhD, MBA
Co-founder, Director,
President & CEO
Kirk Look, CA
Chief Financial Officer
Ernst & Young
Andres Gutierrez, MD, PhD
Chief Medical Officer
Bristol-Myers Squibb
Wayne Pisano, MBA
Chairman of the Board, Oncolytics
Former President, Sanofi Pasteur
Angela Holtham, MBA, ICD.D
Nabisco
Hospital for Sick Children
J. Mark Lievonen, CA
Former President, Sanofi Pasteur
Ontario Institute for Cancer Research
William G. Rice, PhD
President & CEO, Aptose Biosciences
President, CEO & Director of Achillion
Bernd R. Seizinger, MD, PhD
Former President & CEO of GPC Biotech
VP of Oncology Drug Discovery, BMS
Non-Executive Directors
Extensive knowledge of oncology/immunotherapy | Public company experience
Strong commercialization expertise
Management
26. Market and Capital Data
Exchanges
OTCQX: ONCYF
TSX: ONC
Shares Outstanding
(December 31, 2016)
121,258,222
Options
Restricted/performance share units
(December 31, 2016)
7,974,227
1,612,829
Fully Diluted
(December 31, 2016)
130,845,278
Cash / Cash Equivalents /
Short Term Investments
(November 2, 2016)
CDN $17.7 million
USD $13.2 million*
Cash runway Into 2018
26
* Based on FX on November 2, 2016
27. Investment Highlights
27
Novel immuno-oncology viral-agent for systemic administration
exploiting dual activity by cancer cell lysis and anti-tumor immunity
Additional randomized Ph 2 studies to generate OS data in 2017
Pending data in Breast, Ovarian, NSCLC & Colorectal
Near-term focus on chemo-combos for late-stage clinical development
Potential to establish REOLYSIN® as a backbone I/O agent in
combination with checkpoint inhibitors and IMiDs
Extensive patient safety data showing no added significant toxicity
when used as combination with chemotherapy
Manufacturing at scale with sufficient supplies on hand to support late/
stage development and early commercialization
